Laura Cacciaguerra

Laura Cacciaguerra

Auto-generated profile, based on publicly available information

Laura Cacciaguerra

Department of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2019 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
LCLaura Cacciaguerra
Laura Cacciaguerra
AMAlessandro Meani
Alessandro Meani
SMSarlota Mesaros
Sarlota Mesaros
MRMarta Radaelli
Marta Radaelli
JPJacqueline Palace
Jacqueline Palace
MRMaria A. Rocca
Maria A. Rocca

28 March 2023 in Neurology
Verified
Journal Article
Closed access
PDF file
LCLaura Cacciaguerra
Laura Cacciaguerra
PMPearse Morris
Pearse Morris
WTW. Oliver Tobin
W. Oliver Tobin
JCJohn J. Chen
John J. Chen
SBSamantha A. Banks
Samantha A. Banks
EFEoin P. Flanagan
Eoin P. Flanagan
Background and Objectives. Studies on tumefactive brain lesions in myelin-oligodendrocyte-glycoprotein-IgG-associated disease (MOGAD) are lacking. We sought to characterize the frequency, clinical, laboratory, and MRI features of these lesions in MOGAD and compare them to multiple sclerosis (MS) and aquaporin-4-IgG-positive-neuromyelitis-optica-spectrum-disorder (AQP4+NMOSD). Methods. We retrospectively searched 194 MOGAD and 359 AQP4+NMOSD patients with clinical/MRI details available from the Mayo Clinic databases and included those with ≥1 tumefactive brain lesion (maximum transverse diameter ≥2 cm) on MRI. Tumefactive MS patients were identified using the Mayo Clinic medical-record-linkage-system. Binary multivariable stepwise logistic regression identified independent predictors of MOGAD diagnosis; Cox proportional regression models were used to assess the risk of relapsing disease and gait aid in tumefactive vs. non-tumefactive MOGAD patients. Results. We included 108 patients with tumefactive demyelination (MOGAD=43; AQP4+NMOSD=16; MS=49). Tumefactive lesions were more frequent among MOGAD (43/194[22%]) than AQP4+NMOSD (16/359[5%]) (p<0.001). Risk of relapse and need for gait aid were similar in tumefactive and non-tumefactive MOGAD. Clinical features more frequent in MOGAD than MS included headache (18/43[42%] vs. 10/49[20%]; p=0.03) and somnolence (12/43[28%] vs. 2/49[4%]; p=0.003), the latter also more frequent than AQP4+NMOSD (0/16[0%]; p=0.02). The presence of: peripheral T2-hypointense rim, T1-hypointensity, diffusion restriction (particularly an arc pattern), ring enhancement, Balo’-like or cystic appearance favored MS over MOGAD (p<0.001). MRI features were broadly similar in MOGAD and AQP4+NMOSD, except for more frequent diffusion restriction in AQP4+NMOSD (10/15[67%]) than MOGAD (11/42[26%], p=0.005). Cerebrospinal fluid analysis revealed less frequent positive oligoclonal bands in MOGAD (2/37[5%]) than MS (30/43[70%]) (p<0.001) and higher median white cell count in MOGAD than MS (33 vs. 6 cells/µl, p<0.001). At baseline, independent predictors of MOGAD diagnosis were presence of somnolence/headache, absence of T2-hypointense rim, lack of T1-hypointensity, and no diffusion restriction (Nagelkerke R Squared=0.67). Tumefactive lesion resolution was more common in MOGAD than MS or AQP4+NMOSD and improved model performance. Discussion. Tumefactive lesions are frequent in MOGAD but are not associated with a worse prognosis. The clinical, MRI, and CSF attributes of tumefactive MOGAD differ from tumefactive MS, and are more similar to tumefactive AQP4+NMOSD with the exception of lesion resolution, which favors MOGAD.

28 May 2024 in Neurology
Verified
Journal Article
Open access
LCLaura Cacciaguerra
Laura Cacciaguerra
OAOmar Abdel-Mannan
Omar Abdel-Mannan
DCDimitrios Champsas
Dimitrios Champsas
KMKshitij Mankad
Kshitij Mankad
KKKarl N. Krecke
Karl N. Krecke
EFEoin P. Flanagan
Eoin P. Flanagan
Knowledge of the evolution of CNS demyelinating lesions within attacks could assist diagnosis. We evaluated intra-attack lesion dynamics in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) vs multiple sclerosis (MS) and aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder (AQP4+NMOSD). This retrospective observational multicenter study included consecutive patients from Mayo Clinic (USA) and Great Ormond Street Hospital for Children (UK). Inclusion criteria were as follows: (1) MOGAD, MS, or AQP4+NMOSD diagnosis; (2) availability of ≥2 brain MRIs (within 30 days of attack onset); and (3) brain involvement (i.e., ≥1 T2 lesion) on ≥1 brain MRI. The initial and subsequent brain MRIs within a single attack were evaluated for the following: new T2 lesions(s); resolved T2 lesion(s); both; or no change. This was compared between MOGAD, MS, and AQP4+NMOSD attacks. We used the Mann-Whitney U test and χ2/Fisher exact test for statistical analysis. Our cohort included 55 patients with MOGAD (median age, 14 years; interquartile range [IQR] 5-34; female sex, 29 [53%]) for a total of 58 attacks. The comparison groups included 38 patients with MS, and 19 with AQP4+NMOSD. In MOGAD, the initial brain MRI (median of 5 days from onset [IQR 3-9]) was normal in 6/58 (10%) attacks despite cerebral symptoms (i.e., radiologic lag). The commonest reason for repeat MRI was clinical worsening or no improvement (33/56 [59%] attacks with details available). When compared with the first MRI, the second intra-attack MRI (median of 8 days from initial scan [IQR 5-13]) showed the following: new T2 lesion(s) 27/58 (47%); stability 24/58 (41%); resolution of T2 lesion(s) 4/58 (7%); or both new and resolved T2 lesions 3/58 (5%). Findings were similar between children and adults. Steroid treatment was associated with resolution of ≥1 T2 lesion (6/28 [21%] vs 1/30 [3%], p = 0.048) and reduced the likelihood of new T2 lesions (9/28 vs 18/30, p = 0.03). Intra-attack MRI changes favored MOGAD (34/58 [59%]) over MS (10/38 [26%], p = 0.002) and AQP4+NMOSD (4/19 [21%], p = 0.007). Resolution of ≥1 T2 lesions was exclusive to MOGAD (7/58 [12%]). Radiologic lag is common within MOGAD attacks. Dynamic imaging with frequent appearance and occasional disappearance of lesions within a single attack suggest MOGAD diagnosis over MS and AQP4+NMOSD. These findings have implications for clinical practice, clinical trial attack adjudication, and understanding of MOGAD pathogenesis.

1 September 2020 in Radiology
Verified
Journal Article
Closed access
RBRaffaello Bonacchi
Raffaello Bonacchi
EPElisabetta Pagani
Elisabetta Pagani
AMAlessandro Meani
Alessandro Meani
LCLaura Cacciaguerra
Laura Cacciaguerra
PPPaolo Preziosa
Paolo Preziosa
MRMaria A. Rocca
Maria A. Rocca
Cervical cord damage assessed with multiparametric MRI explains a substantial proportion of disease course in multiple sclerosis. Background In multiple sclerosis (MS), knowledge about how spinal cord abnormalities translate into clinical manifestations is incomplete. Comprehensive, multiparametric MRI studies are useful in t...

1 October 2020 in Radiology
Verified
Journal Article
Closed access
LCLaura Cacciaguerra
Laura Cacciaguerra
PVPaola Valsasina
Paola Valsasina
SMSarlota Mesaros
Sarlota Mesaros
VMVittorio Martinelli
Vittorio Martinelli
JDJelena S. Drulović
Jelena S. Drulović
MRMaria A. Rocca
Maria A. Rocca
In neuromyelitis optica spectrum disorders, spinal cord lesions at MRI were mainly distributed in the upper cervical cord and in the gray matter, and were spatially associated with atrophy and corr... Background The spinal cord is commonly involved in patients with neuromyelitis optica spectrum disorders (NMOSDs). However, the relationship between inflammation and atrophy remains unclear. Purpos...

1 August 2019 in Atherosclerosis
Verified
Journal Article
Closed access
EAEnrico Ammirati
Enrico Ammirati
FMFrancesco Moroni
Francesco Moroni
MMMarco Magnoni
Marco Magnoni
MRMaria A. Rocca
Maria A. Rocca
NANicoletta Anzalone
Nicoletta Anzalone
PCPaolo G. Camici
Paolo G. Camici